Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the rapid virologic response (RVR) at combination
therapy (CT) Week 4 between groups receiving a standard combination peginterferon
alfa-2b/viramidine dosing regimen versus a cohort that receives 4 weeks of viramidine
monotherapy prior to the start of peginterferon alfa-2b/viramidine combination therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.